Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
An expert discusses how a registry of gastrointestinal symptoms is leading research during COVID-19.
As researchers try to grasp every aspect of the novel coronavirus disease 2019 (COVID-19), a worldwide database for inflammatory bowel disease (IBD) patients is having a meaningful impact.
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is a registry that allows clinicians to monitor and report on outcomes of COVID-19 occurring in IBD patients in an effort to maintain real-time data on whether certain diseases or treatments tend to cause worse viral outcomes.
In an interview with HCPLive®, Erica Brenner, MD, Pediatric Gastroenterology, University of North Carolina, explains how the database will allow researchers to be flexible in their approach to the ongoing pandemic.
By having real-time data, Brenner said experts continue to agree with the current guidelines of IBD patients on immunosuppressants should continue to take their treatment and are not at a higher risk of more severe outcomes.
However, there is also a need to approach each patient’s circumstances differently.
“I think it is important to take it on a case-by-case basis because in some situations if a patient has contracted COVID-19 than their doctor may recommend delaying the dose of that medication, at least until symptoms have resolved,” Brenner said.
Brenner currently serves on the SECURE-IBD International Advisory Committee.